• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00
    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Euromonitor International Names Synergy Pro-Argi-9+ the World's #1 L-Arginine Supplement

    LEHI, Utah, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Synergy Worldwide, a division of Nature's Sunshine Products, today announced that Euromonitor International has named Pro-Argi-9+ the world's #1 l-arginine supplement,* reinforcing the product's growing global momentum and Synergy's leadership in the health and wellness space. Synergy's flagship product, Pro-Argi-9+ offers a unique formula with clinically researched ingredients featuring L-Arginine to support nitric oxide production and promote healthy circulation and blood flow throughout the body. With this certification, Pro-Argi-9+ will continue to serve as the cornerstone of Synergy's mission to help people push the boundaries of their po

    12/15/25 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form 10-Q filed by Nature's Sunshine Products Inc.

    10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 5:11:13 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 4:44:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    10/15/25 3:45:37 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Brower Nathan G gifted 1,500 shares, decreasing direct ownership by 3% to 45,235 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    12/16/25 3:00:13 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & President, Europe Yates Bryant J sold $37,893 worth of shares (1,700 units at $22.29), decreasing direct ownership by 2% to 98,604 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    12/16/25 2:59:34 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & President, Asia Norman Daniel C sold $181,767 worth of shares (8,884 units at $20.46) and gifted 3,571 shares, decreasing direct ownership by 16% to 63,065 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    11/19/25 6:28:03 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Third Quarter 2025 Conference Call for Thursday, November 6, 2025, at 5:00 p.m. ET

    LEHI, Utah, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, November 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, November 6, 2025Time: 5:00 p.m. Eastern time (3:00 p

    10/23/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Second Quarter 2025 Results

    LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4% to $114.8 million compared to $110.6 million (up 2% in constant currency).GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share.Adjusted EBITDA was up 8% to $11.3 million compared to $10.4 million. Management Commentary "We deli

    7/31/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Announces Leadership Transition Plan

    Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

    6/2/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care